Explorations into the mechanism and potential of the antiviral activity of BOLD-100 as a treatment for COVID-19

BOLD-100 is a promising new drug that initial studies have shown has potent activity against the SARS-CoV-2 (the cause of COVID-19) in cell culture experiments. Before being able to start clinical studies with BOLD-100, additional research into the mechanism of action is required, plus testing the safety and efficacy of BOLD-100 in animal models of COVID-19. The purpose of this project is to utilize a range of cell culture and animal models to test BOLD-100 against COVID-19 to better understand the drug.

Investigations into the mechanism of action and potential in idiopathic pulmonary fibrosis of the novel ruthenium based therapeutic BOLD-100

Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease lung disease with unknown cause. There are limited treatment options for IPF and investigations into new treatment options is needed. BOLD-100 is a clinical-stage small molecule that is currently being investigated as a treatment option in oncology and viral infections. The pathway that BOLD-100 impacts, the unfolded protein response, is important in IPF and therefore this project’s objective is to use preclinical models to test whether BOLD-100 can affect development of IPF.

Determining the antiviral properties and mechanism of actions of BOLD-100 against SARS-CoV-2 in 2D and 3D cell culture systems

BOLD-100 is a promising new clinical stage therapeutic, originally developed for the use as a cancer treatment. The mechanism of action for BOLD-100 suggests that this therapeutic might also protect against infections with viruses, including coronaviruses like SARS-COV-19. The purpose of this project is to test the antiviral efficacy of BOLD-100 against SARS·COV-19 in 20 and 30 cell culture models, and then investigate the mechanism of action. These results will help define BOLD-100 as an antiviral treatment and support clinical investigations into BOLD-100 for the treatment of COVID-19.

Cellular inflammatory and anti-viral effects of BOLD-100, a novel therapeutic agent in development for COVID-19

Bold-100 is a promising new drug that has been studied as a treatment for cancer. Because of the way it works in cells, there is reason to believe that it may also help protect against infections with viruses like SARS-CoV2 (the cause of COVID-19). The purpose of this project is to study the effects of Bold-100 on cells derived from the human intestine, which are susceptible to SARS-CoV2 infection, to help determine the way the drug effects normal cellular functions and their response to viral infections.